HomeCompareARHCF vs JNJ

ARHCF vs JNJ: Dividend Comparison 2026

ARHCF yields 3.73% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARHCF wins by $89.9K in total portfolio value
10 years
ARHCF
ARHCF
● Live price
3.73%
Share price
$11.87
Annual div
$0.44
5Y div CAGR
38%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$110.0K
Annual income
$35,436.17
Full ARHCF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — ARHCF vs JNJ

📍 ARHCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARHCFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARHCF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARHCF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARHCF
Annual income on $10K today (after 15% tax)
$317.42/yr
After 10yr DRIP, annual income (after tax)
$30,120.74/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, ARHCF beats the other by $29,417.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARHCF + JNJ for your $10,000?

ARHCF: 50%JNJ: 50%
100% JNJ50/50100% ARHCF
Portfolio after 10yr
$65.0K
Annual income
$18,131.97/yr
Blended yield
27.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ARHCF
No analyst data
Altman Z
2.7
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARHCF buys
0
JNJ buys
0
No recent congressional trades found for ARHCF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARHCFJNJ
Forward yield3.73%3.36%
Annual dividend / share$0.44$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR38%5.8%
Portfolio after 10y$110.0K$20.0K
Annual income after 10y$35,436.17$827.78
Total dividends collected$81.4K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ARHCF vs JNJ ($10,000, DRIP)

YearARHCF PortfolioARHCF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,215$515.34$10,676$355.77+$539.00ARHCF
2$12,746$745.43$11,407$389.39+$1.3KARHCF
3$14,731$1,092.59$12,198$426.53+$2.5KARHCF
4$17,390$1,628.56$13,056$467.62+$4.3KARHCF
5$21,087$2,479.63$13,987$513.12+$7.1KARHCF
6$26,441$3,877.88$14,998$563.56+$11.4KARHCF
7$34,563$6,271.21$16,098$619.52+$18.5KARHCF
8$47,555$10,572.56$17,295$681.69+$30.3KARHCF
9$69,645$18,761.12$18,599$750.82+$51.0KARHCF
10$109,957$35,436.17$20,022$827.78+$89.9KARHCF

ARHCF vs JNJ: Complete Analysis 2026

ARHCFStock

Alfresa Holdings Corporation, through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally. It is involved in the ethical pharmaceuticals wholesaling business that offers diagnostic reagents and medical devices/equipment to hospitals, clinics, and dispensing pharmacies. The company also engages in self-medication products wholesaling business that offers over-the-counter drugs, including health foods, supplements, and other products to drug stores and pharmacies. In addition, it manufactures and markets active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents, and medical devices, as well as undertakes contract manufacturing of pharmaceuticals. Further, the company's medical-related business includes its dispensing pharmacy and other medical-related activities. Alfresa Holdings Corporation was incorporated in 2003 and is based in Tokyo, Japan.

Full ARHCF Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this ARHCF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARHCF vs SCHDARHCF vs JEPIARHCF vs OARHCF vs KOARHCF vs MAINARHCF vs ABBVARHCF vs MRKARHCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.